Drug-drug interactions (DDIs) are a significant clinical and public health burden, especially for older adults. This burden will increase further as the population ages and the degree of polypharmacy increases. Knowledge about DDIs comes from many sources, with rigorous population-based studies of clinical outcomes providing the most clinically useful information. Because very few population DDI studies have been performed, there is profound disagreement among the DDI compendia about which drug pairs cause clinically important DDIs. Further, uncertainty about which potential DDIs are clinically important has hampered efforts to mitigate the effects of DDIs, such as computerized decision support. Population studies of the clinical effects of DDIs are therefore badly needed, and should be integrated with research on the biological basis of DDIs. In this renewal application, we propose to extend our approach to population DDI studies in two important and innovative ways: 1) by actively and explicitly incorporating mechanistic considerations; and 2) by implementing a sequential approach of initially identifying and quantifying risk, then, where warranted based on this step, characterizing important DDIs further, with the goal of providing the basis for future efforts to mitigate risk. Based on an extensive and structured consultative process to identify research foci, we propose to conduct a series of population DDI studies using a large 5-state Medicaid/Medicare dataset. These studies will examine hypothesized interactions involving lipid lowering drugs, anti-clotting drugs, and oral anti-diabetic drugs, three drug classes with enormous relevance for older adults, and with high potential for causing clinically important DDIs. Thus, we will study potential DDIs of great clinical and public health importance, especially to older adults, and in the process develop data that will help elucidate the mechanisms of these potential DDIs.
Drug-drug interactions (DDIs) are a significant clinical and public health burden, especially for older adults. However, little is known about the clinical importance of most potential DDIs. We will conduct large population studies of the clinical importance of potential DDIs affecting lipid lowering, anti-clotting, and anti-diabetic therapies, addressing potential DDIs of great clinical and public health importance.
|Ertefaie, Ashkan; Small, Dylan S; Ji, Xinyao et al. (2018) Statistical Power for Trend-in-trend Design. Epidemiology 29:e21-e23|
|Leonard, Charles E; Brensinger, Colleen M; Aquilante, Christina L et al. (2018) Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia. Diabetes Care 41:713-722|
|Leonard, Charles E; Han, Xu; Brensinger, Colleen M et al. (2018) Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study. Pharmacoepidemiol Drug Saf 27:9-18|
|Leonard, Charles E; Hennessy, Sean; Han, Xu et al. (2017) Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. Trends Endocrinol Metab 28:561-586|
|Leonard, Charles E; Brensinger, Colleen M; Bilker, Warren B et al. (2017) Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. Int J Cardiol 228:761-770|
|Ji, Xinyao; Small, Dylan S; Leonard, Charles E et al. (2017) The Trend-in-trend Research Design for Causal Inference. Epidemiology 28:529-536|
|Leonard, Charles E; Brensinger, Colleen M; Bilker, Warren B et al. (2017) Thromboembolic and neurologic sequelae of discontinuation of an antihyperlipidemic drug during ongoing warfarin therapy. Sci Rep 7:18037|
|Han, Xu; Chiang, ChienWei; Leonard, Charles E et al. (2017) Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues. Epidemiology 28:459-468|
|Leonard, Charles E; Brensinger, Colleen M; Nam, Young Hee et al. (2017) The quality of Medicaid and Medicare data obtained from CMS and its contractors: implications for pharmacoepidemiology. BMC Health Serv Res 17:304|
|Li, L (2017) Precision Medicine in Pharmacometrics and Systems Pharmacology. CPT Pharmacometrics Syst Pharmacol 6:151-152|
Showing the most recent 10 out of 43 publications